Home / NEWS / Top News / GoodRx files to go public with a rare characteristic: Profits

GoodRx files to go public with a rare characteristic: Profits

Doug Hirsch, Co-Founder and C0-CEO of GoodRx.

Heidi Grudging | CNBC

GoodRx, a company that helps consumers access prescription drugs at a discount, filed to go public on Friday. The following will list on the Nasdaq under the symbol GDRX.

It’s part of a recent spate of IPO filings from tech retinues, including data analytics provider Palantir, data storage company Snowflake and telemedicine provider Amwell. 

But GoodRx has one utensils these other fast-growing companies do not: A record of consistent profitability.

According to the filing, the company earned $55 million in profit for primary half of 2020, up from $31 million in the first half of 2019 — a jump of 75%. Revenues for the first half of 2020 were $257 million, up from $173 million in the to begin half of 2019, for growth of 48%.

In 2019, it pulled in $66 million in profit on $388 million in revenue. The filing guides profits all the way back to 2016, the earliest year for which financial information is included, and the company previously told CNBC that it’s been productive on-and-off since 2013.

GoodRx’s profitability is a rarity among start-ups filing to go public. Another notable example is Zoom, the under-the-radar videoconferencing software that made its debut in April of 2019. That partnership’s stock is up more than eightfold since its debut and has gained 339% this year, as the global coronavirus pandemic hold in check people home and spurred demand for new ways to communicate remotely.

GoodRx, which is based in Southern California, was set up in 2011 by Facebook veteran Doug Hirsch and serial software entrepreneur Trevor Bezdek. The company saw a need to recondition transparency in the highly complex world of prescription drugs. So it built a set of discount cards and coupons for consumers to take to the pharmacopoeia, often allowing them to get a lower price.

It makes its money by collecting fees from the pharmacy benefits administrators, or PBMs, that it works with whenever consumers present their GoodRx coupon at the pharmacy. About 17 million being use GoodRx every month. Going forward, it plans to expand into new areas, including telemedicine.

However, the duty could take a hit if policymakers move to upend the drug supply chain. If consumers were covered by insurance and deaden prices were more transparent and affordable, there would be less of a need for GoodRx.

Hirsch has previously believed: “If America as a country decided to keep all Americans healthy and things were upfront and transparent, there would be no requisite for GoodRx. I don’t suspect that’ll happen, but if it did, I’d happily hang up my hat and move on to another problem.”

The IPO is being led by Morgan Stanley, Goldman Sachs and JP Morgan. The presence has previously raised financing from private equity firms specializing in technology and health, including Silver Lake and Francisco Participants. It was valued around $2.8 billion in a 2018 financing round.

GoodRx was no. 20 in this year’s CNBC Disruptor 50 heel over of promising private companies.

Check Also

Trump tariffs could lead to a summer drop-off in economic activity after an ‘artificially high’ start, Chicago Fed chief says

Work owners and CEOs are already stocking up on inventory, and some American shoppers are …

Leave a Reply

Your email address will not be published. Required fields are marked *